Jazz Pharma director withholds 743 shares for tax
A Jazz Pharmaceuticals director had 743 shares withheld on August 31, 2026 to cover taxes from restricted stock unit vesting, rather than selling shares in the open market.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc director Ted W. Love reported dispositions of 743 Ordinary Shares on August 31, 2026. Two separate share withholdings of 6 and 737 shares were used to pay tax obligations triggered by the vesting of previously granted restricted stock units. These were administrative tax-withholding events, not open-market sales, and no Rule 10b5-1 trading plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Ordinary Shares F1 | 6 | $244.0633 | $1K |
| Tax Withholding | Ordinary Shares F1 | 737 | $241.3899 | $178K |
Footnotes (1)
- F1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Key Figures
Key Terms
restricted stock units financial
tax obligations financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did JAZZ director Ted W. Love report on August 31, 2026?
Were the JAZZ insider transactions open-market sales?
Did the JAZZ Form 4 indicate use of a Rule 10b5-1 trading plan?
What type of security was involved in the JAZZ insider’s Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.